StockData

Agenus vs Ginkgo Bioworks

AGEN and DNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGEN and DNA compare

Ginkgo Bioworks is the larger company, worth 2.0 times as much as Agenus ($560M against $283M).

Agenus grew revenue faster over the last twelve months (30.5% versus −46.8% for Ginkgo Bioworks).

Ginkgo Bioworks scores higher on the StockData Score (9 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGENDNA
Size and price
Market cap$283M$560M
Share price$6.29$8.32
Change, 1 year45.3%3.6%
Change, 5 years−90.3%−98.3%
Beta (5Y)1.012.29
Employees81485
StockData Score
Total score39 (better)
Valuation score12 (better)
Growth score2 (better)0
Performance score02 (better)
Health score05 (better)
Dividend score00
Valuation
P/S2.1× (better)5.0×
P/B–1.3×
EV/EBITDA7.0×–
FCF yield−34.8%−31.2% (better)
Fair value–$9.57
Margin of safety–13.1%
Growth
Revenue growth (TTM)30.5% (better)−46.8%
Revenue growth, 5Y average5.3%17.3% (better)
Profitability
Gross margin99.5%–
Operating margin27.3% (better)−260%
Net margin–−260%
FCF margin−74.2% (better)−156%
Return on equity–−56.3%
Return on invested capital–−118%
Financial health
Debt / equity–0.00
Net debt / EBITDA0.28–
Interest coverage0.6×–
Current ratio0.344.57 (better)
Altman Z-score−16.54−8.83 (better)
Piotroski F-score–3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions31.7%53.7%
Held by insiders6.6%–
Insider net buying, 12 months–−$5.0M
Superinvestors holding–1
Short interest, % of float18.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.